Due to the reduced event rate and sample size in the subgroup analysis, it cannot be excluded that some subgroups were underpowered with a risk of Type II error, so that a significant effect of SGLT2 inhibitors in preventing AF may have been missed in some subgroups. Here, SLC5A2 is linked to atrial fibrillation.